What is Morgan Stanley's price target for RYTM?

Morgan Stanley's latest stated price target for Rhythm Pharmaceuticals Inc. (RYTM) is $55, from its action on Dec 19, 2023.

What is Morgan Stanley's rating on RYTM?

Morgan Stanley rates RYTM Overweight, a bullish rating, as of Dec 19, 2023.

When did Morgan Stanley last change its view on RYTM?

On Dec 19, 2023, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $29 to $55.

Analyst firms · Morgan Stanley · RYTM

Morgan Stanley RYTM price target and rating history

Rhythm Pharmaceuticals Inc. (RYTM) · Health Care

Morgan Stanley rates Rhythm Pharmaceuticals Inc. (RYTM) Overweight with a $55 price target, as of its latest action on Dec 19, 2023. It has published 3 rating actions on RYTM since August 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a RYTM price target in the last 12 months, the median target is $134.50.

Current rating: Overweight
Price target: $55
Median target, all firms: $134.50
Actions on RYTM: 3

Morgan Stanley price target on RYTM

Morgan Stanley price target on RYTM, each point a stated target, August 2021 to December 2023. Targets before December 2023 (multiplied by 2) are adjusted for a stock split, going by the prior target Morgan Stanley restated.

Every Morgan Stanley rating on RYTM

Dec 19, 2023
UpgradeMorgan Stanley upgrades to Overweight from Equal-Weight, price target $29 to $55
Nov 19, 2021
DowngradeMorgan Stanley downgrades to Equal-Weight from Overweight, price target $50 to $15
Aug 4, 2021
ReiterateMorgan Stanley cuts its price target to $54 from $57, keeps Overweight

How other firms rate RYTM

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
William Blair	Outperform		Oct 16, 2026
Wolfe Research	Outperform		Sep 17, 2026
Leerink Partners	Outperform	$133	Sep 14, 2026
Deutsche Bank	Hold	$120	Aug 28, 2026
RBC Capital Markets	Outperform	$478	Feb 19, 2026
Citigroup	Buy	$136	Nov 25, 2025

Questions about Morgan Stanley and RYTM

What is Morgan Stanley's price target for RYTM?: Morgan Stanley's latest stated price target for Rhythm Pharmaceuticals Inc. (RYTM) is $55, from its action on Dec 19, 2023.
What is Morgan Stanley's rating on RYTM?: Morgan Stanley rates RYTM Overweight, a bullish rating, as of Dec 19, 2023.
When did Morgan Stanley last change its view on RYTM?: On Dec 19, 2023, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $29 to $55.
How does Morgan Stanley's RYTM target compare with other analysts?: Across 4 firms with a RYTM price target in the last 12 months, the median target is $134.50.

More RYTM rating histories

All Morgan Stanley ratings RYTM news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.